A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 07 Nov 2023
At a glance
- Drugs TAS 3681 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 22 Sep 2023 Planned End Date changed from 1 Oct 2023 to 1 Mar 2024.
- 01 Feb 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 01 Feb 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.